Introduction
============

Acute myelocytic leukemia (AML) is a tumor derived from the myeloid line of blood cells, in which abnormal cells in the bone marrow and blood are rapidly generated ([@b1-etm-0-0-8846]). AML is characterized by the proliferation and abnormal differentiation of cells of the hematopoietic system in bone marrow, blood and other tissues ([@b2-etm-0-0-8846]). The typical clinical symptoms of patients with AML are shortness of breath, fatigue, increased risk of infection, and easy bleeding and bruising ([@b3-etm-0-0-8846]). The risk factors of AML mainly include smoking, benzene exposure, myelodysplastic syndrome, and previous radiation therapy or chemotherapy ([@b4-etm-0-0-8846],[@b5-etm-0-0-8846]). AML is more frequent in elderly men, and it progresses rapidly without immediate therapy ([@b6-etm-0-0-8846]). AML affects approximately one million individuals and resulted in 147,000 deaths globally in 2015([@b7-etm-0-0-8846]). The pathogenesis of AML needs to be further investigated to decrease the prevalence and mortality of AML.

Long non-coding RNAs (lncRNAs) are transcripts with a length \>200 nucleotides. lncRNAs have no protein coding potential but are implicated in various biological functions, including cell cycle, apoptosis, epigenetic regulation and imprinting ([@b8-etm-0-0-8846]). lncRNA expression is closely associated with recurrent mutations, and some lncRNAs play important roles in the AML therapeutic response and clinical survival ([@b9-etm-0-0-8846]). HOX transcript antisense RNA expression is upregulated in *de novo* patients with AML, which is strongly associated with the clinicopathological prognosis of patients with AML ([@b10-etm-0-0-8846],[@b11-etm-0-0-8846]). Insulin-like growth factor type I receptor (IGF1R) antisense imprinted non-protein coding RNA is associated with long range IGF1R DNA interactions and upregulation of the IGF pathway in AML, and is a potential tumor suppressor and therapeutic target for the disease ([@b12-etm-0-0-8846]). lncRNA H19 (imprinted maternally expressed transcript) is an independent prognostic biomarker for patients with tumors, and its expression is significantly upregulated in AML and may play a role in AML cell proliferation ([@b13-etm-0-0-8846]). lncRNA RUNXOR \[runt related transcription factor 1 (RUNX1) overlapping promoter-derived noncoding RNA) is located in the RUNX1 locus ([@b14-etm-0-0-8846]). Overexpressed RUNXOR may serve as a tumor suppressor through RUNX1 and scaffolding mediated translocation of DNA correlated in AML ([@b15-etm-0-0-8846]). However, the lncRNAs associated with the prognosis of AML have not been fully reported.

In the present study, prognosis-associated lncRNAs were screened to construct a risk score system for AML. Additionally, the potential functions of the key lncRNAs were predicted. The data could be valuable in clarifying the prognostic mechanisms of AML and could contribute to the prognostic prediction of the disease.

Materials and methods
=====================

### Data source

All available RNA-sequencing data of AML samples were searched using The Cancer Genome Atlas (TCGA) database (<https://cancergenome.nih.gov/>) on March 17, 2018. In total, 187 AML samples with RNA-sequencing data were obtained from TCGA ([@b16-etm-0-0-8846],[@b17-etm-0-0-8846]). According to the age information of the samples, 111 samples from patients under the age of 14 years were included. The 111 samples were randomly divided into two groups (56 samples in the training set and 55 samples in the validation set). The clinical information of the samples in each group is presented in [Table I](#tI-etm-0-0-8846){ref-type="table"}.

### Differential expression analysis

Among the 56 AML samples in the training set, the median survival time was 54.13 months. It was assumed that samples from patients with a short survival were high risk, and patients with longer survival being indicative of relatively low risk. Combining these assumptions with the median survival time established 54.13±18 months as the cut-off value to classify different prognostic samples. Samples with a survival time \<36 months who had died were classified into the bad prognosis group (n=20). Samples with a survival time \>72 months who were still alive were divided into the good prognosis group (n=21). The differentially expressed lncRNAs (DE-lncRNAs) between the two groups were selected using the DEseq package (version 1.30.0; <https://bioconductor.org/packages/release/bioc/html/DESeq.html>) ([@b18-etm-0-0-8846]) and edgeR package (version 3.20.9; <http://bioconductor.org/packages/release/bioc/html/edgeR.html>) ([@b19-etm-0-0-8846]) in R, which were also used in other previous studies ([@b20-etm-0-0-8846]). The false discovery rate (FDR) \<0.05 and log fold change (FC) \>1 were defined as the thresholds. By comparing the results of the two screening methods, the overlapped DE-lncRNAs were taken as the final DE-lncRNAs. Based on the expressions of the DE-lncRNAs in the training set, the bidirectional hierarchical clustering using the pheatmap package in R (version 1.0.8; <https://cran.r-project.org/web/packages/pheatmap/index.html>) ([@b23-etm-0-0-8846]) was performed.

### Identification of prognosis-associated lncRNAs and clinical factors

Using the survival package in R (version 2.41.3; <https://cran.r-project.org/web/packages/survival/index.html>) ([@b24-etm-0-0-8846]), univariate and multivariate Cox regression analysis was conducted for the 56 AML samples in the training set to screen the prognosis-associated lncRNAs and clinical factors. The log-rank P\<0.05 was set as the threshold for the significant results.

### Construction and evaluation of risk score system

Based on the prognosis-associated lncRNAs, the optimal lncRNA combination was selected using the Cox-Proportional Hazards (Cox-PH) model in R package penalized (version 0.9.50; <https://cran.r-project.org/web/packages/penalized/index.html>) ([@b25-etm-0-0-8846]). The optimal parameter 'λ' in the Cox-PH model was obtained through the cross-validation likelihood (cvl) for 1,000 times. The risk score system was constructed for AML samples combined with the linear combination of the lncRNA expression with regression coefficient weighting. The formula for calculating the prognostic index (PI) of each sample was as follows:

PI=β lncRNA1 x exprlncRNA1 + β lncRNA2 x exprlncRNA2 + ··· + β lncRNAn x exprlncRNAn

The PI of each sample in the training set was calculated based on the aforementioned formula, and the median PI was utilized as the cut-off value of the good and bad prognosis samples. A Kaplan-Meier (KM) curve ([@b26-etm-0-0-8846]) was used to calculate the survival time in the two groups when stratified by different prognostic factors, based on which to evaluate the prognosis difference between the good and bad prognosis groups using a certain prognostic factor, and an area under the receiver operating characteristic (AUROC) curve ([@b27-etm-0-0-8846]) was applied to assess the performance of prognostic prediction effectiveness using the risk score system. Then, the risk score system was used to evaluate the prognosis of the samples in the validation set.

### Construction of the lncRNA-mRNA expression correlation network

In the training set, the samples were divided into the good and bad prognosis groups according to their PIs in the predictive risk score system model. The differentially expressed mRNAs (DE-mRNAs) between the good and bad prognosis groups were analyzed using the edgeR package ([@b19-etm-0-0-8846]), with the thresholds of FDR \<0.05 and log FC \>1. Then, the Pearson correlation coefficients (PCCs) ([@b28-etm-0-0-8846]) of the DE-mRNAs and the lncRNAs involved in the risk score system were calculated. Finally, the DE-mRNAs with PPC \>0.5 were obtained for constructing the lncRNA-mRNA expression correlation network.

### Pathway enrichment analysis

Based on Gene Set Enrichment Analysis (GSEA; <http://software.broadinstitute.org/gsea/index.jsp>) ([@b29-etm-0-0-8846]), pathway enrichment analysis for the mRNAs in the network was performed to identify the significant pathways correlated with key lncRNAs. The pathways with nominal P\<0.05 were considered as significant results.

Results
=======

### Differential expression analysis

After the AML samples in the training set were classified into the bad and good prognosis groups, the DEseq package and edgeR package were used for the selection of DE-lncRNAs ([Fig. 1A](#f1-etm-0-0-8846){ref-type="fig"}). A total of 61 overlapped DE-lncRNAs were obtained by comparing the results of the two screening methods ([Fig. 1B](#f1-etm-0-0-8846){ref-type="fig"}). The clustering heatmap of the 61 DE-lncRNAs suggested the samples could be distinguished by these DE-lncRNAs ([Fig. 1C](#f1-etm-0-0-8846){ref-type="fig"}).

### Identification of prognosis-associated lncRNAs and clinical factors

In the training set, 61 lncRNAs were subjected to univariate Cox regression analysis. A total of 48 lncRNAs were significantly associated with prognosis (P\<0.05; data not shown). Univariate and multivariate Cox regression analysis indicated that relapse was significantly associated with prognosis in the training set, the validation set and the entire set (Table II; P\<0.05). Therefore, relapse was identified as an independent clinical factor with prognostic significance. The KM curves of relapse and the overall survival (OS) of the samples in the training set, the validation set and the entire set are presented in [Fig. 2A](#f2-etm-0-0-8846){ref-type="fig"}. The results showed that the AML samples without relapse had better clinical prognosis, which was consistent with the actual situation.

### Construction and evaluation of the risk score system

Based on the expression matrix of the 48 prognosis-associated lncRNAs in the training set, the optimal lncRNA combination was analyzed using the Cox-PH model using the penalized package. After performing the 1,000 times cvl algorithm, the maximum cvl value was-108.177 when the parameter 'λ' was set as 24.34156 ([Fig. 2B](#f2-etm-0-0-8846){ref-type="fig"}). With the optimal parameter, the optimal lncRNA combination involving 14 lncRNAs \[LINC00639, probable E3 ubiquitin-protein ligase makorin-3 (MKRN3)-antisense RNA 1 (AS1), LINC02060, LINC02133, LINC01726, LINC00240, paired box protein Pax8 (PAX8)-AS1, zinc finger protein 32 (ZNF32)-AS1, probable leucine-tRNA ligase, mitochondrial (LARS2)-AS1, Ras association domain family member 8 (RASSF8)-AS1, E74-like factor 3 (ELF3)-AS1, WASH complex subunit 5-antisense RNA 1 (WASHC5)-AS1, MYB-AS1 and FAR1 intronic transcript 1 (FAR1-IT1)\] was screened ([Fig. 2C](#f2-etm-0-0-8846){ref-type="fig"}; [Table III](#tIII-etm-0-0-8846){ref-type="table"}) using the Cox-PH model.

The risk score system was constructed and the formula for calculating PIs was: PI=(0.20989291) x ExpLINC00639+ (0.06638359) x Exp MKRN3-AS1+(0.3139191) x ExpLINC02060 +(0.42299789) x ExpLINC02133+(-0.19338239) x ExpLINC01726 +(-0.2969476) x ExpLINC00240+(0.73636164) x ExpPAX8-AS1+ (0.02132678) x ExpZNF32-AS1+(0.1805946) x ExpLARS2-AS1+ (0.53198533) x ExpRASSF8-AS1+(0.41975344) x ExpELF3-AS1+ (0.33392756) x ExpWASHC5-AS1+(0.62016856) x ExpMYB-AS1+(0.02508178) x Exp FAR1-IT1.

Subsequently, the performance of the prognostic prediction of the risk score system for the samples in the training set, the validation set and the entire set were evaluated using KM curves and AUROC curves ([Fig. 3](#f3-etm-0-0-8846){ref-type="fig"}). The expression levels of the 14 optimal lncRNAs in the aforementioned sets downloaded from TCGA are presented in [Fig. 4](#f4-etm-0-0-8846){ref-type="fig"}, where all 14 lncRNAs exhibited distinct expression profiles between bad and good prognosis groups. The PIs, OS and expression heatmap of the 14 lncRNAs in the training set, the validation set and the entire set are presented in [Fig. 5](#f5-etm-0-0-8846){ref-type="fig"}.

### Construction of the lncRNA-mRNA expression correlation network

Based on the PIs of the samples in the training set, the samples were divided into the good and bad prognosis groups and 730 DE-mRNAs (718 upregulated and 12 downregulated) between the two groups were identified. The PCC of the expression level of each DE-mRNA and PI was calculated, and then the top 100 DE-mRNAs with highest absolute values of PCC were used for sample clustering ([Fig. 6](#f6-etm-0-0-8846){ref-type="fig"}). Furthermore, the PCCs between the DE-mRNAs and the 14 optimal lncRNAs were calculated. The lncRNA-mRNA expression correlation network was constructed with the criterion of PCC \<0.5 ([Fig. 7](#f7-etm-0-0-8846){ref-type="fig"}).

### Pathway enrichment analysis

Based on GSEA pathway enrichment analysis, axon guidance \[involving semaphorin 3C (SEMA3C), semaphorin 6D and netrin 4\] and the Wnt signaling pathway \[involving Dickkopf-related protein 4, 1-phosphatidylinositol 4,5-biphosphate phosphodiesterase β 4 and secreted frizzled-related protein 5 (SFRP5)\] were separately associated with the lncRNAs LARS2-AS1 and WASHC5-AS1, respectively ([Table IV](#tIV-etm-0-0-8846){ref-type="table"}).

Discussion
==========

In recent decades, bioinformatics methods have developed rapidly and are being applied for the analysis of gene expression profiles to determine the pathogenesis of human diseases ([@b30-etm-0-0-8846]). A total of six genes (triggering receptor expressed on myeloid cells like 2, solute carrier family 7 member 11, NLR family pyrin domain containing 2, DNA damage inducible transcript 4, lymphocyte specific protein 1 and C-type lectin domain containing 11A) have been identified as prognostic indicators of AML combining TCGA data with a Gene Expression Omnibus dataset ([@b31-etm-0-0-8846]). In total, two lncRNAs (NONHSAT027612.2 and NONHSAT134556.2) have been implicated in the pathogenesis of childhood acute lymphoblastic leukemia (ALL) ([@b32-etm-0-0-8846]). However, the prognosis has not been investigated ([@b32-etm-0-0-8846]). In another previous study, although both lncRNAs and their relationships with prognosis had been examined in AML, the authors focused on the competing endogenous RNAs regulation network ([@b33-etm-0-0-8846]). The predictive role of lncRNAs on the prognosis of AML remains obscure.

In the present study, 61 DE-lncRNAs between the good and bad prognosis groups were obtained. Of these, 48 lncRNAs were significantly associated with prognosis. Cox regression analysis demonstrated that relapse was significantly associated with the prognosis of patients with AML and was an independent prognostic factor. From the 48 prognosis-associated lncRNAs, the optimal lncRNA combination involving 14 lncRNAs was screened to construct the risk score system. Subsequently, 730 DE-mRNAs were identified for the good and bad prognosis groups divided by PIs, and the lncRNA-mRNA expression correlation network was constructed.

The Wilms\' tumor gene 1 (WT1) is overexpressed in AML and functions as an oncogene ([@b34-etm-0-0-8846]). Therefore, it is a therapeutic target of AML. PAX8 is a physiological regulator of WT1 that accounts for its upregulation ([@b35-etm-0-0-8846]). The lncRNA PAX8-AS1 located in the upstream region of the PAX8 gene regulates the expression of the gene ([@b36-etm-0-0-8846]). The rs4848320 and rs6726151 polymorphisms of PAX8-AS1 can significantly increase the risk of ALL ([@b37-etm-0-0-8846]). Therefore, PAX8-AS1 may act as a risk factor for childhood ALL ([@b37-etm-0-0-8846]). CREB-binding protein/P300 coactivation derived by MYB is necessary for ALL and AML, and MYB activity plays a critical role in maintaining AML ([@b38-etm-0-0-8846]). MYB expression is increased in T cell ALL, and the oncogene MYB could be a therapeutic target for the disease ([@b39-etm-0-0-8846],[@b40-etm-0-0-8846]). These findings suggested that PAX8-AS1 and MYB-AS1 might be associated with the pathogenesis of patients with AML.

LINC00240-Kruppel-like factor 3 crosstalk is mediated by microRNA-26b-5p in esophageal squamous cell carcinoma (ESCC) and its loss may be involved in the oncogenesis of ESCC ([@b41-etm-0-0-8846]). ZNF32 is a transcription factor closely associated with oxidative stress and protects tumor cells against oxidative stress-induced cell death ([@b42-etm-0-0-8846]). Therefore, targeting ZNF32 may suppress multidrug resistance during chemotherapy and improve the clinical outcome of patients with lung adenocarcinoma ([@b41-etm-0-0-8846],[@b43-etm-0-0-8846]). RASSF8 expression is negatively associated with lymph node metastasis and survival of patients with ESCC ([@b44-etm-0-0-8846]). Therefore, RASSF8 is a tumor suppressor and a candidate therapeutic target for the disease ([@b44-etm-0-0-8846]). The low expression of E74-like factor 3 (ELF3) is significantly correlated with decreased survival of patients with ovarian cancer, and ELF3 is a favorable prognostic biomarker for the tumor ([@b45-etm-0-0-8846]). Although LINC00240, ZNF32-AS1, RASSF8-AS1 and ELF3-AS1 have not been reported to be related to AML, their roles in other tumors were identified. Based on the findings of the present study, they could be prognostic factors for AML. Therefore, LINC00240, ZNF32-AS1, RASSF8-AS1 and ELF3-AS1 might also influence the prognosis of AML.

Dysregulated axon guidance molecules (AGMs) function as tumor suppressors or oncogenes in breast cancer, which may be promising targets for the prognosis and therapy of tumors ([@b46-etm-0-0-8846]). Some AGMs play roles in mediating cell migration and apoptosis in tumorigenic tissues, suggesting that promoting or inhibiting the activity of AGMs may be novel approaches for treating tumors ([@b47-etm-0-0-8846]). Semaphorins, which are one type of AGMs, serve as tumor suppressors ([@b48-etm-0-0-8846]). Of note, semaphorin 3B (SEMA3B) could act as a tumor inhibitor in the early stage of breast cancer, and could also promote metastasis during the late stage of the cancer ([@b49-etm-0-0-8846]). The role of SEMA3C has not been fully reported, but it belongs to the AGMs that promote tumor metastasis ([@b46-etm-0-0-8846]). In the present study, SEMA3C was significantly enriched in the axon guidance pathway, and it was associated with the lncRNA LARS2-AS1, suggesting that expression of SEMA3C may be regulated by LARS2-AS1, and the alteration of the gene might disturb the pathway, which might affect the pathogenesis of AML. However, these regulatory regulations remain to be experimentally validated.

The Wnt signaling pathway is overexpressed in most cases of AML and targeting the WNT/lymphoid enhancer-binding factor 1 signaling cascade may be used for developing novel therapies for AML ([@b50-etm-0-0-8846],[@b51-etm-0-0-8846]). The Wnt signaling pathway is directly mediated by several secreted antagonist families, such as the SFRP family ([@b52-etm-0-0-8846]). In AML, this pathway is mediated by methylation of Wnt antagonists ([@b53-etm-0-0-8846]). In the present study, SFRP5 was significantly associated with the Wnt signaling pathway and was indirectly regulated by the lncRNA WASHC5-AS1 in the interaction network, suggesting the interactions between them might influence the signaling pathway, and regulate the development of AML. Nonetheless, these interactions need to be experimentally validated.

In the present study, relapse was identified as an independent prognostic factor in both the training and validation datasets, suggesting that relapse could affect the prognostic risk using this 14-lncRNA predictive system. However, more clinical evidence is required.

Although comprehensive bioinformatics analysis has been conducted, there were several limitations of the present study. The expressions of these lncRNAs and genes were not validated *in vitro* and the interactions were not confirmed. In addition, the predictions of prognostic roles of these lncRNAs also need the support of further clinical data. More experiments should be designed and conducted to support the present results.

In conclusion, a 14-lncRNA (including PAX8-AS1 and MYB-AS1) risk score system might be effective for the prediction of AML prognosis. There were two pathways identified from the GSEA pathway enrichment analysis; axon guidance, which might involve SEMA3C and LARS2-AS1, and the Wnt signaling pathway, which might include the interaction of SFRP5 and WASHC5-AS1. These two identified pathways might be important factors that affect the prognosis of childhood AML.

Not applicable.

Funding
=======

The present study was supported by Medical Scientific Research Project of Henan Province (grant no. 2018020905), Medical Scientific Research Project of Henan Province (grant no. SB201903035), Medical and Health Program of Luoyang Science & Technology Project (grant no. 1910014A).

Availability of data and materials
==================================

All data used in this study are available in TCGA database (<https://portal.gdc.cancer.gov/>).

Authors\' contributions
=======================

HRW designed this study; SLG, BL, XYX, WLW, SYW and TL performed the data analysis. The final version of the manuscript was read and approved by all authors.

Ethics approval and consent to participate
==========================================

Not applicable.

Patient consent for publication
===============================

Not applicable.

Competing interests
===================

The authors declare that they have no competing interests.

![Differential expression analysis between good and bad prognosis groups. (A) Dysregulated lncRNAs identified separately by the DEseq package (top) and edgeR package (bottom). Red and green represent upregulated and downregulated lncRNAs in the good prognosis group, respectively. (B) Venn diagram for comparing the results of the two screening methods. (C) Clustering heatmap of the 61 intersected lncRNAs. Red and green indicate bad and good prognosis groups, respectively. FDR, false discovery rate; FC, fold change; lncRNA, long non-coding RNA.](etm-20-02-1521-g00){#f1-etm-0-0-8846}

![Kaplan-Meier curves and the selection of the optimal combination. (A) Kaplan-Meier curves for relapse in the training set (left), the validation set (middle), and the entire set (right). (B) Curve for selecting the optimal parameter 'λ' using cvl (the junction of the red dashed lines indicates the value of lambda is 24.34156 when the maximum value-108.177 is obtained for cvl). (C) Coefficient distribution diagram of the 14 optimal lncRNAs. cvl, cross-validation likelihood; lncRNA, long non-coding RNA.](etm-20-02-1521-g01){#f2-etm-0-0-8846}

![KM curves and AUROC curves. (A) KM curves showing the OS (left) and RFS (middle), and the AUROC curve (right) for the training set. (B) KM curves showing the OS (left) and RFS (middle) and the AUROC curve (right) for the validation set. (C) KM curves showing the OS (left) and RFS (middle) and the AUROC curve (right) for the entire set. KM, Kaplan-Meier; AUROC, area under the received operating characteristic; AUC, area under curve; OS, overall survival; RFS, relapse-free survival.](etm-20-02-1521-g02){#f3-etm-0-0-8846}

![Expression levels of the 14 optimal lncRNAs. (A) Expression levels of the 14 optimal lncRNAs in the training set. (B) Expression levels of the 14 optimal lncRNAs in the validation set. (C) Expression levels of the 14 optimal lncRNAs in the entire set. Green and red represent good and bad prognosis groups, respectively. ^\*^P\<0.05; ^\*\*^P\<0.01 and ^\*\*\*^P\<0.005 vs. respective good prognostic group. lncRNA, long non-coding RNA.](etm-20-02-1521-g03){#f4-etm-0-0-8846}

![PIs, OS and expression heatmap of the 14 optimal lncRNAs. (A) PIs (top), OS (middle) and expression heatmap (bottom) of the 14 optimal lncRNAs in the training set. (B) PIs (top), OS (middle) and expression heatmap (bottom) of the 14 optimal lncRNAs in the validation set. (C) PIs (top), OS (middle) and expression heatmap (bottom) of the 14 optimal lncRNAs in the entire set. PI, prognostic index; OS, overall survival; lncRNA, long non-coding RNA.](etm-20-02-1521-g04){#f5-etm-0-0-8846}

![Clustering heatmap for the top 100 differentially expressed mRNAs with higher absolute value of Pearson correlation coefficient.](etm-20-02-1521-g05){#f6-etm-0-0-8846}

![lncRNA-mRNA expression correlation network. Circles and squares represent mRNAs and lncRNAs, respectively. The colors ranging from light to dark indicate the increased degree of upregulation in the good prognosis group. lncRNA, long non-coding RNA; FC, fold change.](etm-20-02-1521-g06){#f7-etm-0-0-8846}

###### 

Clinical information of the samples in the training set, the validation set and the entire set.

  Clinical characteristics                              Training set, n=56    Validation set, n=55    Entire set, n=111
  ----------------------------------------------------- --------------------- ----------------------- ------------------------
  Age, years, mean ± SD                                 5.99±4.26             5.81±4.32               5.91±4.27
  Sex, male/female                                      32/24                 31/24                   63/48
  WBC at diagnosis, 10^9^/l, mean ± SD                  64.56±74.03           97.09±113.96            80.67±96.86
  Bone marrow leukemic blast percentage, %, mean ± SD   69.51±20.44           72.99±20.39             71.19±20.39
  Peripheral blasts, %, mean ± SD                       49.61±28.76           57.7±30.09              53.62±29.58
  CNS disease, yes/no                                   3/53                  4/51                    7/104
  Chloroma, yes/no/-                                    3/53                  6/48/1                  9/101/1
  FAB Category, M0/M1/M2/M3/M4/M5/M6/M7/-               0/3/9/0/18/12/1/6/7   3/11/14/0/10/11/1/1/4   3/14/23/0/28/23/2/7/11
  FLT3/ITD mutation, yes/no                             4/52                  5/50                    9/102
  NPM mutation, yes/no/-                                0/52/4                5/50/0                  5/4/102
  CEBPA mutation, yes/no/-                              2/52/2                4/51                    6/103/2
  WT1 mutation, yes/no                                  2/50/4                4/51                    6/101/4
  Relapse, yes/no                                       37/19                 40/15                   77/34
  Relapse free survival time, months, mean ± SD         33.01±34.84           31.52±32.42             32.27±33.52
  Death, dead/alive                                     24/32                 24/31                   48/63
  Overall survival time, months, mean ± SD              54.13±34.76           55.97±36.08             55.04±35.27

-, data unavailable; WBC, white blood cell; CNS, central nervous system; FAB, French-American-British; FLT3, receptor-type tyrosine-protein kinase FTL3; ITD, internal tandem duplications; NPM, nucleophosmin; CEBPA, CCAAT enhancer binding protein α; WTM, Wilms\' tumor gene 1.

###### 

Prognostic analysis of clinical factors for the samples in the training set, the validation set and the entire set.

  A, Training set, n=56                                                                                        
  ----------------------------------------------------- --------------------- ----------------------- -------- ---------
  Age, years, mean ± SD                                 1.103                 0.045                   1.010    0.881
  Sex, male/female                                      0.966                 0.934                   1.062    0.905
  WBC at diagnosis, 10^9^/l, mean ± SD                  0.996                 0.296                   0.997    0.530
  Bone marrow leukemic blast percentage, %, mean ± SD   1.011                 0.321                   1.020    0.245
  Peripheral blasts, %, mean ± SD                       0.987                 0.077                   0.992    0.527
  Chloroma, yes/no/-                                    0.702                 0.728                   0.594    0.732
  FAB Category, M0/M1/M2/M3/M4/M5/M6/M7/-               1.103                 0.471                   1.095    0.692
  FLT3/ITD mutation, yes/no                             2.480                 0.130                   1.297    0.840
  WT1 mutation, yes/no                                  6.876                 0.005                   4.549    0.186
  Relapse, yes/no                                       8.259                 0.001                   12.462   0.016
  B, Validation set, n=55                                                                                      
                                                        Univariate analysis   Multivariate analysis            
  Variables                                             HR                    P-value                 HR       P-value
  Age, years, mean ± SD                                 0.864                 0.008                   0.766    0.003
  Sex, male/female                                      1.018                 0.966                   1.249    0.691
  WBC at diagnosis, 10^9^/l, mean ± SD                  1.001                 0.409                   0.998    0.608
  Bone marrow leukemic blast percentage, % mean ± SD    0.992                 0.417                   0.961    0.217
  Peripheral blasts, %, mean ± SD                       1.001                 0.879                   1.029    0.057
  Chloroma, yes/no/-                                    0.574                 0.447                   0.633    0.688
  FAB Category, M0/M1/M2/M3/M4/M5/M6/M7/-               0.852                 0.213                   0.812    0.255
  FLT3/ITD mutation, yes/no                             2.412                 0.145                   9.222    0.073
  WT1 mutation, yes/no                                  2.584                 0.113                   0.656    0.591
  Relapse, yes/no                                       9.150                 0.003                   5.828    0.011
  C, Entire set, n=111                                                                                         
                                                        Univariate analysis   Multivariate analysis            
  Variables                                             HR                    P-value                 HR       P-value
  Age, years, mean ± SD                                 0.981                 0.566                   0.943    0.173
  Sex, male/female                                      0.991                 0.976                   1.031    0.929
  WBC at diagnosis, 10^9^/l, mean ± SD                  1.001                 0.959                   0.998    0.537
  Bone marrow leukemic blast percentage, %, mean ± SD   1.001                 0.925                   0.999    0.911
  Peripheral blasts, %, mean ± SD                       0.995                 0.281                   1.005    0.537
  Chloroma, yes/no/-                                    0.619                 0.416                   0.462    0.301
  FAB Category, M0/M1/M2/M3/M4/M5/M6/M7/-               0.967                 0.705                   1.072    0.528
  FLT3/ITD mutation, yes/no                             2.496                 0.031                   2.268    0.215
  WT1 mutation, yes/no                                  3.388                 0.007                   2.019    0.185
  Relapse, yes/no                                       9.227                 \<0.0001                11.048   0.001

HR, hazard ratio; WBC, white blood cell; FAB, French-American-British; FLT3, receptor-type tyrosine-protein kinase FTL3; ITD, internal tandem duplications; WTM, Wilms\' tumor gene 1.

###### 

Information of the 14 optimal lncRNAs.

  lncRNA       Coef          HR (95% CI)           P-value
  ------------ ------------- --------------------- ----------
  LINC00639    0.20989291    1.075 (1.023-1.130)   0.0025
  MKRN3-AS1    0.06638359    1.054 (1.015-1.096)   0.0038
  LINC02060    0.3139191     1.069 (1.024-1.117)   0.0014
  LINC02133    0.42299789    1.152 (1.061-1.250)   \<0.0001
  LINC01726    -0.19338239   0.938 (0.898-0.979)   0.0023
  LINC00240    -0.2969476    0.945 (0.897-0.996)   0.0302
  PAX8-AS1     0.73636164    1.093 (1.012-1.179)   0.0224
  ZNF32-AS1    0.02132678    1.070 (1.023-1.119)   0.0010
  LARS2-AS1    0.1805946     1.075 (1.019-1.133)   0.0030
  RASSF8-AS1   0.53198533    1.128 (1.023-1.244)   0.0142
  ELF3-AS1     0.41975344    1.223 (1.045-1.431)   0.0205
  WASHC5-AS1   0.33392756    1.195 (1.030-1.387)   0.0076
  MYB-AS1      0.62016856    1.175 (1.038-1.330)   0.0247
  FAR1-IT1     0.02508178    1.135 (1.017-1.267)   0.0325

Coef, coefficient; HR, hazard ratio; CI, confidence interval; lncRNA, long non-coding RNA.

###### 

Pathways significantly associated with LARS2-AS1 and WASHC5-AS1.

  A, LARS2-AS1                                              
  ----------------------- ---------- ---------- ----------- ----------------------
  Axon guidance           0.842324   1.775851   0.0081      SEMA3C, SEMA6D, NTN4
  B, WASHC5-AS1                                             
  Name                    ES         NES        NOM P-val   Genes
  Wnt signaling pathway   -0.6971    -1.4588    0.0081      DKK4, PLCB4, SFRP5

ES, enrichment score; NES, normalized enrichment score; NOM P-val, nominal P-value; AS1, antisense 1; LARS2, probable leucine-tRNA ligase, mitochondrial; WASHC5, WASH complex subunit 5; SEMA3C, semaphorin 3C; SEMA6D, semaphorin 6D; NTN4, netrin 4; DKK4, Dickkopf-related protein 4; PLCB4, 1-phosphatidylinositol 4,5-biphosphate phosphodiesterase β 4; secreted frizzled-related protein 5.
